FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive
immunity, and has the potential to overcome multiple mechanisms of immune checkpoint
inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the
clinical investigation of FT500 as monotherapy and in combination with ICI in subjects with
advanced solid tumors.